anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The overlapping of two or more types of neural autoantibodies in one patient has increasingly been documented in recent years. The coexistence of myelin oligodendrocyte glycoprotein (MOG) and N-methyl-d-aspartate receptor (NMDAR) antibodies is most common, which leads to a unique condition known as the MOG antibody and NMDAR antibody overlapping syndrome (MNOS). Here, we have reviewed the pathogenesis, clinical manifestations, paraclinical features, and treatment of MNOS. Forty-nine patients with MNOS were included in this study. They were young males with a median onset age of 23 years. No tumors were observed in the patients, and 24 of them reported prodromal symptoms. The most common clinical presentations were psychiatric symptoms (35/49) and seizures (25/49). Abnormalities on magnetic resonance imaging involved the brainstem (11/49), cerebellum (9/49), and parietal lobe (9/49). Most patients mostly responded to immunotherapy and had a good long-term prognosis. However, the overall recurrence rate of MNOS was higher than that of mono antibody-positive diseases. The existence of concurrent NMDAR antibodies should be suspected in patients with MOG antibody-associated disease having psychiatric symptoms, seizures, movement disorders, or autonomic dysfunction. Similarly, serum MOG antibody testing should be performed when patients with anti-NMDAR encephalitis present with atypical clinical manifestations, such as visual impairment and limb weakness, and neuroradiological findings, such as optic nerve, spinal cord, or infratentorial involvement or meningeal enhancement. Early detection of the syndrome and prompt treatment can be beneficial for these patients, and maintenance immunosuppressive therapy is recommended due to the high overall recurrence rate of the syndrome.
BACKGROUND: All-cause mortality and cardiovascular disease are increased in subjects with metabolic syndrome (MetS). Risk scores are used to predict individual risk of heart disease. We performed a long-term follow-up study to investigate whether risk scores and cardiovascular risk factors such as arterial stiffness, high-sensitive C-reactive protein (hs-CRP) and oxidized LDL (OxLDL) can be used to predict cardiovascular events in Finnish men with MetS.
METHODS: After baseline measurements we followed 105 Finnish men aged 30 to 65 years with MetS for a mean period of 16.4 years. The primary outcome of the study was a composite of myocardial infarction, stroke, symptomatic vascular disease diagnosed with invasive angiography, coronary or peripheral revascularization, amputation due to peripheral vascular disease, cardiovascular death and non-cardiovascular death. The endpoints were retrieved from electronic medical records.
RESULTS: The number of acute myocardial infarctions and strokes during the first 10 years was lower than estimated by FINRISK score but SCORE predicted cardiovascular death correctly. During the whole follow-up period, 27 of 105 participants (25.8%) had 30 endpoint events. The incidence of the primary composite outcome was significantly lower in subjects with hs-CRP < 1.0 mg/L than in subjects with hs-CRP ≥ 1.0 mg/L (6 of 41 subjects [14.6%] vs. 21 of 64 subjects [32.8%]; p = 0.036). The incidence of the primary composite outcome was higher among subjects with large artery elasticity classified as borderline compared to subjects with normal large artery elasticity (5 of 10 subjects [50%] vs. 22 of 93 subjects [24%]; p = 0.05). There was no difference in the incidence of primary composite outcome in groups with different degrees of small artery elasticity or different level of oxLDL.
CONCLUSIONS: Men with MetS who had hs-CRP ≥ 1.0 mg/L had higher risk for CVD and all-cause mortality than those with hs-CRP of < 1.0 mg/L. This also applies to subjects with borderline decreased large artery elasticity. The amount of OxLDL had no predictive value on the incidence of CVD and all-cause mortality. Men with MetS participating in the Hämeenlinna Metabolic Syndrome Research Program without lifestyle or drug intervention had better outcome for myocardial infarction or stroke than estimated by the FINRISK score.
TRIAL REGISTRATION: ClinicalTrials.gov NCT01119404 retrospectively registered 07/05/2010.
Thalidomide has found new uses as a tumor anti-angiogenesis agent that is capable of diminishing the proliferation of angiogenesis-dependent solid malignancies. Distantly metastatic, unresectable medullary thyroid carcinomas, as well as de-differentiated papillary and follicular thyroid carcinomas, which no longer concentrate radioiodine, have no known effective systemic therapies. We have verified, in the context of a completed phase 2 clinical trial, that thalidomide has significant activity in thyroid carcinomas that are no longer radioiodine avid and are rapidly progressive. This activity has only limited durability of around 7 months and is associated with significant toxicities of sedation, constipation and neuropathy.

REVLIMID® (lenalidomide) is an analog of thalidomide with the chemical name, alpha-(3-aminophthalimido) glutarimide. REVLIMID® is noted to be more potent than thalidomide in inhibiting the production of TNF-alpha. It has more than doubled the inhibition of microvessel growth at the same concentration as thalidomide in a rat aorta angiogenesis model as well as greatly enhanced activity as an IMiD. Most importantly, it lacks much of the toxicity of thalidomide, particularly in regards to somnolence, neuropathy, or biochemical effects. In fact, patients with multiple myeloma, known to be resistant to thalidomide, were still seen to exhibit clinical responses to REVLIMID®. This makes REVLIMID® an appropriate agent to investigate in a phase 2 trial in thyroid carcinoma.
The invention discloses an antibody or antigen binding fragment specifically binding to HAdV55 and application thereof. The antibody or antigen binding fragment comprises a heavy chain variable region comprising a heavy chain CDR1 as shown in SEQ ID NO. 5, a heavy chain CDR2 as shown in SEQ ID NO. 6 and a heavy chain CDR3 as shown in SEQ ID NO. 7; the light chain variable region comprises a light chain CDR1 shown as SEQ ID NO. 8, a light chain CDR2 shown as SEQ ID NO. 9 and a light chain CDR3 shown as SEQ ID NO. 10. The antibody or antigen binding fragment has the advantages of high humanization degree and high neutralization titer, takes the Hexon protein of the HAdV55 as an action target spot, and can be widely applied to the practical diagnosis and treatment scheme of the HAdV 55.
The present invention relates to the field of drug delivery. More specifically, the present invention provides methods and compositions useful for transepithelial delivery of therapeutics, vaccines and diagnostics. In certain embodiments, a composition comprises a transcytosis enhancer, a cargo agent, and a pharmaceutically acceptable carrier. In a specific embodiment, the transcytosis enhancer comprises N-ethylmaleimide or derivative thereof. In a specific embodiment, the transcytosis enhancer is a Serine Protease Autotransporters of Enterobactericeae (SPATE) protease. In a more specific embodiment, the SPATE protease is Extracellular Serine Protease Plasmid (O157)-encoded) (EspP).
Safe and effective analgesia is an important unmet medical need in children. Despite efforts to promote non-pharmacologic interventions, drug treatment remains the standard of care for children experiencing severe pain following surgery. Inadequate pain relief after invasive surgery, and side effects from analgesics such as morphine occur frequently in up to 50% of children. A study of patient-controlled analgesia morphine use after spine surgery in adolescents observed a 45% incidence of postoperative nausea and vomiting 15% incidence of pruritis and 7% incidence of respiratory depression. Among the drugs available, the opioids, specifically morphine is the most commonly employed. Morphine has a narrow therapeutic index, with the most fatal toxicity being respiratory depression. For morphine, like most opioids, there is a fine balance in dosing regimen between optimal pain control and safety in terms of decreasing morphine's respiratory depressant/ sedative side effects. Inadequate pain relief and analgesic side effects have major clinical, behavioral and economic consequences. Neither evidence-based dosing guidelines nor rigorous documentation of therapeutic benefit for morphine has been ascertained in the pediatric patient population. Despite aggressive pain management after spine surgery, findings showed that neither children's pain nor their analgesic use diminished significantly over time. As such, there is a critical knowledge gap in the medical literature that significantly impacts the pediatric pain management. In recognition of this therapeutic challenge the investigators plan to evaluate the determinants of inter-individual differences in opioid analgesic responsiveness and adverse effects in children. Adolescents following spine surgery have a great variability in morphine requirements with greater use as they became older. Analgesic dosing is dependent on appreciation of the interplay between pharmacokinetics, pharmacodynamics and therapeutics. These factors are often poorly understood, where the effective control of procedural pain for example, remains problematic. Suitable pharmacological alternatives to opioid treatment for moderate to severe pain in children after surgery are limited and consequently there is a need for a critical evaluation of the existing opioids and research reports.

Recently a number of small studies have shown the association of single nucleotide polymorphism in genes in the pain pathway, with altered pain response to a stimulus or altered response to opioids following a painful procedure. Age, gender, cultural influences, anxiety, type of surgical procedure and genetic factors can all influence the response. By extending follow up of patients to years after surgery, the aims were amended to include evaluation of chronic post-surgical outcomes.

We will be collecting data on pain scores, opioid effects, psychological questionnaires, blood samples and pupillometry data.
This is a prospective, observational study of patients seen in the Holter lab at Scripps Green Hospital and other Scripps Clinic locations. Only patients who have indications for traditional cardiac rhythm monitoring will be enrolled in the study. Patients 18 years or older with suspected arrhythmias capable of providing informed consent will wear both a traditional Holter monitor for up to 48 hours and a Zio® Patch for up to 14 days. Both devices will be initiated at the same time as they do not interfere with one another. This will also allow a direct comparison of the same initial up to 24 hour monitoring period between the two devices. As the Zio® Patch is worn for up to 14 days instead of only 24 hours, it will be assessed if in the physician's opinion (referring physician), waiting for the extended time hinders being able to provide medical care and/or diagnosis for the patient.
This invention is about a convenience meat food, specifically about an edible and portable nutritious health sheep soup. It solves the problems of uncarriable and flavor impurity of traditional sheep soup in current technics. Its charging is a kit beef offal, codonopsis pilosula, cinnamon, Chinese angelica root and ginger. Its preparing method is: Dunk the beef offal and meat in eau douce; cut the codonopsis pilosula and cinnamon into sections; cut the Chinese angelica root and ginger into pieces; fill 100 kilograms water in boiling case; then put the beef offal and Chinese traditional medicine bag into the vase to boil; lastly separately package meat and soup. Not only the flavor is improved, its nutrition components are also increased. It tastes delicious and can reinforce spleen and stomach; it can enrich the blood and is not greasy; it can warm viscera and is not hot. The food and medicine nourish together, and it can tonify kidney and yang; it helps digest and reinforce resisting ability.
Estimates suggest that over 80% of people with COVID-19 may experience mild to no symptoms. The Centers for Disease Control and Prevention (CDC) reported that around 7-8% of positive COVID-19 cases were hospitalized in the first year of the pandemic. A substantial body of evidence points to obesity, sedentary behavior, and low physical activity levels as risk factors for susceptibility to the virus and the severity of symptoms. Obese individuals are 46% more likely to contract the virus than those of normal weight, and those who are physically active have an 11% reduced risk of contracting the virus. Medical experts have also identified obesity, sedentary behavior, and physical inactivity as risk factors for severe COVID-19 symptoms and long COVID. Evidence from bariatric surgery suggests that weight loss decreases the susceptibility and severity of COVID-19. The mechanisms linking obesity, sedentary behavior, and physical activity to COVID-19 are somewhat similar. Obesity, sedentary behavior, and low physical activity are all linked to inflammation, immune dysfunction, and comorbidities such as diabetes and cardiovascular disease that increase COVID-19 risk. Additionally, achieving the recommended 150 min of moderate-intensity exercise seems to be the desired dose for protection from COVID-19.
The invention relates to a traditional Chinese medicine used for treating femur head necrosis. The medicine is characterized in that: the medicine is prepared from materials of: 8-10g of pilose asiabell root, 6-8g of creeping liriope, 6-10g of figwort, 6-8g of white peony root, 6-10g of Szechwan lovage rhizome, 6-8g of suberect spatholobus stem, 8-10g of ma-yuen jobstears seed, 6-8g of dragon's bone, 4-6g of villous amonmum fruit, 6-8g of slenderstyle acanthopanax bark, 4-6g of radix notoginseng, 4-6g of cairo morningglory root or leaf, 6-8g of Japanese clubmoss herb, 6-8g of turtle carapace, and 4-6g of tuckahoe. The materials are selected, mixed, soaked, and are decocted into a decoction of 200ml. The decoction is orally taken twice a day, wherein the decoction is taken in the morning and in the evening, and 100ml of the decoction is taken each time. A treatment course contains 10 days. The traditional Chinese medicine has functions of blood circulation promoting, meridian obstruction removing, stasis eliminating, pain relieving, qi reinforcing, blood nourishing, kidney invigorating, and bone reinforcing. With the medicine, bone tissue microcirculation can be ameliorated, sclerotin can be dredged, blood vessel can be nourished, blood oxygen supply can be promoted, and skeletal normal function can be recovered. With the medicine, clinical treatments can be carried out based on the differentiation of symptoms. The medicine is also advantaged in good curative effect, short treatment course, high recovery rate, low cost, and no toxic or side effect. Therefore, the medicine is worth popularizing.
Recent respiratory outbreaks have garnered substantial attention, yet most respiratory monitoring remains confined to physical signals. Exhaled breath condensate (EBC) harbors rich molecular information that could unveil diverse insights into an individual's health. Unfortunately, challenges related to sample collection and the lack of on-site analytical tools impede the widespread adoption of EBC analysis. Here, we introduce EBCare, a mask-based device for real-time in situ monitoring of EBC biomarkers. Using a tandem cooling strategy, automated microfluidics, highly selective electrochemical biosensors, and a wireless reading circuit, EBCare enables continuous multimodal monitoring of EBC analytes across real-life indoor and outdoor activities. We validated EBCare's usability in assessing metabolic conditions and respiratory airway inflammation in healthy participants, patients with chronic obstructive pulmonary disease or asthma, and patients after COVID-19 infection.
A generalized search engine is provided for abstract data types with skimming and approximate retrieval. According to various embodiments, an abstract data type definition is generated. The abstract data type definition comprises a plurality of field-value pairs. The abstract data type definition is indexed in an index. A document definition is generated. The document definition comprises at least one key value, and further comprises the abstract data type definition. The document definition is indexed in the index.
This is a randomized controlled study evaluating the effectiveness of PEC I, PEC II, Transversus Thoracic plane blocks as the primary anesthetic in participants undergoing subcutaneous implantable defibrillator. There will be two groups; the nerve block group vs. general anesthesia group. The participants in the nerve block group will receive an ultrasound-guided nerve block in the electrophysiology suite prior to the start of the procedure. Participants will get a PEC I block with 10ml of 0.375% ropivacaine, PEC II block with 15ml of 0.375% ropivacaine, 15ml of 0.375% ropivacaine for TTP. PEC I block entails injecting local anesthesia between the pectoralis major and pectoralis minor muscles to anesthetize the medial and lateral pectoral nerves. PEC II block entails injecting local anesthetic between the pectoralis minor and serratus anterior muscles to block the upper intercostal nerves. For Tranversus Thoracic Plane block, local anesthetic will be injected between the internal intercostal muscle and the Transversus Thoracic muscle. The participants in the nerve block group will get mild sedation during the nerve blocks (midazolam 1-2mg IV and fentanyl 50-100mcg IV). After block placement, patient will be given a 0.3mcg/kg bolus of dexmedetomidine, then an infusion of dexmedetomidine 0.4mcg/kg/hr- 0.7mcg/kg/hr r +/- propofol 25mcg/kg/min-100mcg/kg/min for sedation. The general anesthesia group of participants will get the current standard of care with an endotracheal tube with a combination of IV induction medications and volatile anesthetic. Research assistant will hand an enclosed envelope to the anesthesiologists with the name of the group consented patient will be in.

Intraoperatively, the anesthesiologist will note if supplemental opioids and local anesthetic was required. Postoperatively, the PACU nurse will be asked to document pain scores according to the Visual Analog Scale (VAS) and total dose of opioids given. The distribution of the sensory block and motor weakness will be documented in the anesthesiologist's PACU discharge note. For postoperative data collection, opioid consumption totals and the pain scores at 30 minutes after arrival in PACU and at discharge.
Sequential Randomization: Participants randomized to receive mindfulness as a Phase II intervention will discontinue their Phase I treatment. The Mindfulness-Oriented Recovery Enhancement (MORE) treatment was designed specifically to address symptoms and underlying mechanisms of chronic pain in the military context and is led over 8 individual sessions.
BACKGROUND: Limited information is available regarding the impact of sarcopenia on the prognosis of antiangiogenic therapy in individuals with advanced non-small cell lung cancer (NSCLC). This study primarily sought to examine the prognostic significance of sarcopenia in individuals with advanced NSCLC undergoing antiangiogenic therapy.
METHODS: We retrospectively enrolled all patients who met the inclusion and exclusion criteria from 2019 to 2021 at Nantong University Hospital. Patients were grouped according to the presence or absence of sarcopenia. After propensity score matching (PSM), progression-free survival (PFS), overall survival (OS), and adverse event rates were compared between the two groups. Factors associated with prognosis were screened using univariate and multivariate analyses.
RESULTS: A total of 267 patients were included, with a total of 201 matched at baseline after PSM (77 in the sarcopenia group and 124 in the non-sarcopenia group). The sarcopenia group had lower PFS (p = 0.043) and OS (p = 0.011) than the non-sarcopenia group and a higher incidence of adverse events (p = 0.044). Multivariate analysis suggested that sarcopenia is an independent prognostic risk factor for OS in advanced NSCLC patients receiving antiangiogenic therapies (p = 0.009). Results of subgroup analyses showed some differences in the impact of sarcopenia on survival prognosis in populations with different characteristics.
CONCLUSION: Patients with advanced NSCLC with comorbid sarcopenia exhibit a worse prognosis when treated with antiangiogenic therapy, and preventing and ameliorating sarcopenia may lead to better survival outcomes in patients with advanced NSCLC.
An analgesic preparation for application to the oral mucosa (including the gingival and lip surfaces) comprises an aqueous or hydroalcoholic gel and a water-soluble salicylate compound dissolved in said gel, said preparation having a pH of from 4 to 7.  Generally, the preparation has a salicylate ion concentration of 2 to 10% by weight.  Salicylate compounds specified are choline, potassium, sodium, calcium and morpholine salicylates. The gelling agent for the preparation may be methyl cellulose, methyl ethyl cellulose, polyoxythylene glycol, polyvinyl pyrrolidone, dextran, gum guar, algin gum, gum acacia or gum tragacanth.  Optional ingredients include antiseptics, e.g. cetyldimethylbenzylammonium chloride, antibiotics, e.g. penicillin and penicillin salts, tyrothricin, tetracycline and neomycin, and flavouring and sweetening agents, e.g. cyclohexylsulphamic acid.
Heavy menstrual bleeding (HMB) is often the presenting symptom for females with inherited bleeding disorders (IBD). Multidisciplinary clinics leverage the expertise of hematologists and women's health specialists. This study characterizes the complexity of HMB management for adolescents with IBDs from a large multidisciplinary clinic. Adolescents often required multiple different menstrual suppression treatments, with only about 20% achieving acceptable suppression with their first treatment. Adolescents switched therapy most often for uncontrolled bleeding, followed by adverse effects, and patient preference. Given the difficulty in achieving adequate menstrual suppression, multidisciplinary clinics offer necessary expertise in accomplishing bleeding control with minimal adverse effects.
Participants will complete computerized surveys to document the frequency of positive and negative emotions experienced in daily life. The attention control group will be given the option to access our positive psychological intervention and associated content via the web at the conclusion of the 12-week data collection phase.
Patients in this group will receive oral acetaminophen and a saline solution placebo through their IV. The enteral formulation will be in the standard tablet form of 500mg per pill. Patients will receive two pills, or 1 gram of acetaminophen.